Skip to main content
SpringerLink
Log in

Targeted Therapy and Their Ocular Complications

  • Chapter
  • First Online:
Clinical Ophthalmic Oncology

Abstract

The rapid advancements in the field of oncology have resulted in the transition from cytotoxic chemotherapeutic agents to molecularly targeted therapies that interfere with cellular signaling pathways important for the survival and propagation of neoplastic cells. Some of these agents have changed the landscape in the management of several hematologic and solid malignancies. Molecularly targeted agents are selected and designed to provide the maximal antitumor affect with the minimal functional alteration of the normal healthy cells. However, the complexity of cellular pathways proves very difficult to design therapeutic agents that do not overlap with the physiologic activities of the normal human tissues. The recognition of a myriad of distinct adverse effects related to the molecularly targeted therapies has emerged over the last decade with their increased clinical usage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol. 2012;6(2):155–76.

    Article  PubMed  CAS  Google Scholar 

  2. Myskowski PL, Halpern AC. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care. 2009;3(4):294–9.

    Article  PubMed  Google Scholar 

  3. Hedhli N, Russell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev. 2011;7(4):221–33.

    Article  PubMed  CAS  Google Scholar 

  4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7.

    Article  PubMed  CAS  Google Scholar 

  5. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 2000;289(5486):1938–42.

    Article  PubMed  CAS  Google Scholar 

  6. Fletcher JA. Role of KIT and platelet-derived growth factor receptors as oncoproteins. Semin Oncol. 2004;31(2 Suppl 6):4–11. Review.

    Article  PubMed  CAS  Google Scholar 

  7. Heuchel R, Berg A, Tallquist M, et al. Platelet-derived growth factor B receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3kinase signaling. Proc Natl Acad Sci U S A. 1999;96:11410–5.

    Article  PubMed  CAS  Google Scholar 

  8. Demetri G, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.

    Article  PubMed  CAS  Google Scholar 

  9. Fraunfelder FW, Solomon J, Druker BJ, Esmaeli B, Kuyl J. Ocular side effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003;19:371–5.

    Article  PubMed  CAS  Google Scholar 

  10. Esmaeli B, Diba R, Ahmadi MA, Saadati HG, Faustina MM, Shepler TR, Talpaz M, Fraunfelder R, Rios MB, Kantarjian H. Periorbital Oedema and epiphora as ocular side effects of imatinib Mesylate (Gleevec). Eye (Lond). 2004;18(7):760–2.

    Article  CAS  Google Scholar 

  11. Breccia M, Gentilini F, Cannella L, Latagliata R, Carmosino I, Frustaci A, Alimena G. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res. 2008;32(7):1022.

    Article  PubMed  CAS  Google Scholar 

  12. Kitzmann AS, Baratz KH, Mohney BG, Pulido JS, Cameron JD, Lee ES, Leof EB. Histologic studies of the intraocular toxicity of imatinib mesylate in rabbits. Eye (Lond). 2008;22(5):712–4.

    Article  CAS  Google Scholar 

  13. Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res. 2012;32(4):1375–7.

    PubMed  CAS  Google Scholar 

  14. Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg. 2005;31:2427–8.

    Article  PubMed  Google Scholar 

  15. Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol. 2008;52(4):331–3.

    Article  PubMed  Google Scholar 

  16. Babu KG, Attili VSS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol. 2007;27:43–4.

    Article  Google Scholar 

  17. Bajel A, Bassili S, Seymour JF. Safe treatment of a patient with CML using dasatinib after prior retinal oedema due to imatinib. Leuk Res. 2008;32(11):1789–90.

    Article  PubMed  CAS  Google Scholar 

  18. Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer. 2013;21(4): 1167–74.

    Article  PubMed  Google Scholar 

  19. Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg. 2007;23:65–6.

    Article  PubMed  Google Scholar 

  20. Zhang G, Basti S, Jampol LM. Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature. Cornea. 2007;26(7):858–60.

    Article  PubMed  Google Scholar 

  21. Saint-Jean A, Sainz de la Maza M, Morral M, Torras J, Quintana R, Molina JJ, Molina-Prat N. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology. 2012;119(9):1798–802.

    Article  PubMed  Google Scholar 

  22. Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med. 2008;59:429–42.

    Article  PubMed  CAS  Google Scholar 

  23. Tullo AB, Esmaeli B, Murray PI, Bristow E, Forsythe BJ, Faulkner K. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Phase I and II clinical trials. Eye (Lond). 2005;19(7):729–38.

    Article  CAS  Google Scholar 

  24. Holubec L, Liska V, Matejka VM, Fiala O, Dreslerova J, Mrazkova P, Treska V, Finek J. The role of cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res. 2012;32(9):4007–11.

    PubMed  CAS  Google Scholar 

  25. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008;19:92–8.

    Article  PubMed  Google Scholar 

  26. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.

    Article  PubMed  CAS  Google Scholar 

  27. Guler M, Yilmaz T, Ozercan I, Elkiran T. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol. 2009;147:703–8.

    Article  PubMed  Google Scholar 

  28. Burris 3rd HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O’Shaughnessy JA. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405.

    Article  PubMed  CAS  Google Scholar 

  29. Saleh M, Bourcier T, Noel G, Speeg-Schatz C, Gaucher D. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol. 2011;50(3):477–8.

    Article  PubMed  Google Scholar 

  30. Braghiroli MI, Sabbaga J, Hoff PM. Bevacizumab: overview of the literature. Expert Rev Anticancer Ther. 2012;12(5):567–80.

    Article  PubMed  CAS  Google Scholar 

  31. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897–908.

    Article  PubMed  CAS  Google Scholar 

  32. Rajendram R, Fraser-Bell S, Kaines A, Michaelides M, Hamilton RD, Esposti SD, Peto T, Egan C, Bunce C, Leslie RD, Hykin PG. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–9.

    Article  PubMed  CAS  Google Scholar 

  33. Sherman JH, Aregawi DG, Lai A, Fathallah-Shaykh HM, Bierman PJ, Linsky K, Larner JM, Newman SA, Schiff D. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology. 2009;73(22):1924–6.

    Article  PubMed  CAS  Google Scholar 

  34. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980–2.

    Article  PubMed  CAS  Google Scholar 

  35. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med. 2006;354:980–2.

    Article  PubMed  Google Scholar 

  36. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25:3559.

    Article  PubMed  Google Scholar 

  37. Khan KH, Fenton A, Murtagh E, McAleer JJ, Clayton A. Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature. Tumori. 2012;98(5):139e–42.

    PubMed  Google Scholar 

  38. Yoong J, Chong G, Hamilton K. Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma. Med Oncol. 2011;28 Suppl 1:S395–7.

    Article  PubMed  Google Scholar 

  39. Wegner A, Khoramnia R. Neurosensory retinal detachment due to sunitinib treatment. Eye (Lond). 2011;25(11):1517–8.

    Article  CAS  Google Scholar 

  40. Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012;8(5):623–33.

    Article  PubMed  CAS  Google Scholar 

  41. Dogan SS, Esmaeli B. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am. 2009;23(1):109–14, ix.

    Article  PubMed  Google Scholar 

  42. Keenan JD, Fram NR, McLeod SD, Strauss EC, Margolis TP. Perifosine-related rapidly progressive corneal ring infiltrate. Cornea. 2010;29(5):583–5.

    Article  PubMed  Google Scholar 

  43. Curran MP. Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs. 2012;72(1): 99–107.

    Article  PubMed  CAS  Google Scholar 

  44. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(1): 103–19.

    Article  PubMed  CAS  Google Scholar 

  45. Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris 3rd HA, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(8):773–81.

    Article  PubMed  CAS  Google Scholar 

  46. Leijen S, Middleton MR, Tresca P, Kraeber-Bodéré F, Dieras V, Scheulen ME, Gupta A, Lopez-Valverde V, Xu ZX, Rueger R, Tessier JJ, Shochat E, Blotner S, Naegelen VM, Schellens JH, Eberhardt WE. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res. 2012;18(17): 4794–805.

    Article  PubMed  CAS  Google Scholar 

  47. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–14.

    Article  PubMed  CAS  Google Scholar 

  48. Jordan EJ, Kelly CM. Vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2012; 13(17):2533–43.

    Article  PubMed  CAS  Google Scholar 

  49. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004;27:478–9.

    Article  PubMed  Google Scholar 

  50. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21): 2691–7.

    Article  PubMed  CAS  Google Scholar 

  51. Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011;27(4):e87–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, University of Louisville, Louisville, KY, USA

    Denis Jusufbegovic

  2. Department of Hematologic Oncology Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA

    Pierre L. Triozzi

  3. Department of Ophthalmic Oncology, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, USA

    Arun D. Singh MD

Authors
  1. Denis Jusufbegovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pierre L. Triozzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arun D. Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arun D. Singh MD .

Editor information

Editors and Affiliations

  1. Dept. of Ophthalmic Oncology, Cole Eye Institute Cleveland Clinic Foundation, Cleveland, Ohio, USA

    Arun D. Singh

  2. Ocular Oncology Service, Dept. of Ophthalmol., University of California, San Francisco, San Francisco, California, USA

    Bertil Damato

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Jusufbegovic, D., Triozzi, P.L., Singh, A.D. (2014). Targeted Therapy and Their Ocular Complications. In: Singh, A., Damato, B. (eds) Clinical Ophthalmic Oncology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40489-4_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-40489-4_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-40488-7

  • Online ISBN: 978-3-642-40489-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation